Buffett said that the most important thing in investment is to choose the right direction. In the past two years, Sino-US competition and cooperation and global fight against the epidemic have become the two biggest backgrounds of the times. The COVID-19 pandemic is still raging in 2022, and the Russian-Ukraine conflict broke out again. Russia is subject to all-round sanctions. The world is facing greater changes, and the population is aging. Medical + hard technology, technological independence + technological innovation are the clearest directions we believe at the moment and are worth continuing to focus. When many people were talking about lying flat, Dingxin chose the right direction and went into battle with unprecedented lightweight equipment and continued to attack!
The world situation is turbulent, and the valuation of the secondary market has been greatly adjusted, which has affected current confidence, but it is often a good opportunity for low-level layout and long-term investment. Dingxin is also the same after the 2020 epidemic. Seizing the opportunity, entering the market, investing in high-quality projects at a lower cost, and surfing the current fluctuations with long-term investment. This is also one of the core reasons why Dingxin Science and Technology Innovation Phase I Fund achieved excellent results. Dingxin Science and Technology Innovation Phase I Fund is Dingxin's third VC fund. It was established in March 2019. It only focuses on the direction of medical and semiconductor hard technology, and has invested a large proportion in the Pre-A and A rounds. As of the end of the first quarter of 2022, the fund has achieved excellent performance of 65% of the annualized IRR.
In the first half of 2022, Dingxin maintained a good pace, whether it was the fundraising and landing of new funds or the investment in new projects, and was repeatedly praised by the industry. Many of Dingxin’s invested companies have also made outstanding progress in the new round of financing, product research and development, and industry recognition.
funds have large scale and high valuations, both of which are the enemies of performance. Dingxin will continue to leverage its early investment advantages, control the scale of funds, control the valuation of a single project, and strive to obtain excellent returns for investors through long-term high-quality investments.
Dingxin Progress
Dingxin Honor
In May 2022, Dingxin Capital ranked among the top investment list of "Top 50 of China's Best Early-stage Venture Capital Institutions in 2021";
In May 2022, Dingxin Capital was selected as the CHC Medical Consulting × CITIC Securities "Top 30 of the Best Medical and Health Investment Institutions in 2021".
Team Honor
In March 2022, Ms. Hu Hui, founding partner of Dingxin Capital, once again ranked in the "2021 Best Female Investor List of China's Equity Investment Industry".
In May 2022, partner Mr. Pan Tao was named the "Best Young Investor in China's Equity Investment Industry in 2021".
In May 2022, partner Mr. Deng Ning was selected as the "Top 50 Most Influential Investors of 2021".
fund newly established
Zhuhai Dingxin Zhenhua Fund: Focus on semiconductor hard technology investment and complete fund establishment and filing.
Nanjing Dingxin Jiankang Fund: Focus on medical Jiankang investment and complete fund establishment and filing.
Nanjing Chuangyi Dingxin Medical Fund: It is a new phase of medical investment fund recently initiated and established by Dingxin Capital in Gulou District, Nanjing. It has received strong support from the two-level government investment guidance funds of Nanjing Municipal Science and Technology Innovation Fund and the Gulou District Industrial Development Guidance Fund. As a major project, Chuangyi Dingxin Medical Fund will be launched in Gulou District and will soon complete the establishment and filing of the fund.
investment and take action
Medical and Health Direction: In March 2022, Yingpai Pharmaceutical officially announced the completion of the D1 round of financing, and Dingxin Capital participated in the investment. This is also Dingxin Capital's first US dollar fund.
Hard technology direction: Dingxin Capital completed the Pre-A round investment of a certain automotive TSN chip project and Pre-A round + investment of a certain WiFi6/7 chip project in the first half of 2022, maintaining the early investment rhythm in the field of hard technology, waiting for the company's official announcement.
project progress
follow-up financing
medical health
- Antike Medical has completed nearly 100 million yuan in round C financing, and continues to build an innovative electrophysiology platform
This round of financing was led by Zhang Keherun Fund, followed by Huangpu Pharmaceutical Fund and Shanlan Capital, and the old shareholder Dingxin Capital continues to invest additionally, and Haoyue Capital serves as the exclusive financial advisor. This round of financing will be used for the research and development, clinical registration and commercial promotion of Antiac Medical's innovative electrophysiological products. In October 2018, Dingxin Capital completed its exclusive investment in Pre-A round of Antik Medical and continued to invest in its subsequent round of financing.
- Tangji Medical has completed nearly 100 million yuan in round B financing to create a new treatment for minimally invasive intervention of metabolic diseases
This round of financing is jointly invested by Shenzhen Tuojin Venture Capital Fund and Wuxi Guolian New Chuang. The funds will be used to complete the registered clinical trials of Tangji Medical's national innovative medical device "gastric transfer stent system" and the research and development and clinical trial preparations of multiple new products in the R&D pipeline. In June 2018, Tangji Medical received a Pre-A round of investment led by Dingxin Capital. In May 2021, Tangji Medical received investment from BV Baidu venture capital, followed by Dingxin Capital, Langmafeng Venture Capital and other institutions.
Technology
- Automotive grade MCU chip company Zhixin Semiconductor has completed several rounds of financing for hundreds of millions of yuan
National Big Fund, Industrial Capital , and well-known investment institutions jointly support the specific details, waiting for the company's official announcement.
- Yisixin Technology, a leading company in the domestic DPU chip, completed a round A financing of hundreds of millions of yuan
This round of financing was jointly led by JLSemi Jingluo Semiconductor and Renchen Semiconductor and its joint investor, MassAve Global, and strongly followed by Xiongniu Capital and existing shareholders Lishi Ventures and Oakseed Ventures. This financing will accelerate the commercial application of Yisixin Technology in the fields of DPU chips and smart network cards, and thus promote the market-oriented and large-scale development of the domestic DPU industry. In August 2021, Dingxin Capital participated in Yisixin Technology's Pre-A round investment.
Enterprise Honors
Medical and Health
Yingpai Pharmaceutical: Selected in "2021 Wanfang Family Office ·Hurun China Cheetah Enterprise"
Antike Medical, Huamu Medical: Both were selected in "2021 Medical and Health Most Investment Value TOP 50"
Zifu Medical, Tangji Medical: Both were selected in the 2022 Top 100 Future Medical Industries "Value Field List"
Technology
Wuhan Minxin Semiconductor: 25G CWDM4 DFB laser won the "2021 Excellent Technology Award"
YiShi Technology: won the TOP100 list of Shenzhen, Hong Kong, Macau Science and Technology Innovation Enterprises
YiShi Technology: passed Shenzhen's 2021 "Specialized, Specialized, Specialized, and New" Small and Medium Enterprises certification
FeiBi Electronics: won the Shenzhen "Specialized, Specialized, Specialized, and New" Enterprise Title
Product/R&D/Market, etc. Progress
Medical and Health
Bo Pfizer entered
- Its SIS material - Boruijin® Oral Repair Membrane has been officially approved as Class III Medical Device Registration Certificate . It is the fourth Class III certificate of animal source products obtained by Borui after entering the "SIS Materials Legion" after inguinal hernia biological patch, anal fistula plug, and dura repair tablet. This is also China's first oral soft tissue repair membrane product with SIS biomaterials.
- Dural patch tablets were awarded the Beijing New Technology and New Products (Services) Certificate
- Two articles SIS hydrogel research results were published in SCI core journal
- Yingpai Pharmaceutical
- Senaparib combined with temozolomide clinical trial application was approved in China
- ATR inhibitor IMP9064 clinical trial application was approved in China
- ATR inhibitor IMP9064 completed the first subject dosing in the United States
- Announced Dr. Timothy Yap joined its scientific advisory committee
- Preliminary clinical data on dose climbing and dose expansion of Senaparib combined with temozolomide was published at the 2022 American Society of Clinical Oncology Annual Meeting
Zifu Medical
-Zifu Medical and China People's Insurance have reached a strategic cooperation with , and insured all examined persons using Dasheng® magnetron capsule endoscopy system products a gastrointestinal medical health insurance
Sangji Medical
-Sangji Medical's "Preparation process for metal coating stents at low pH" independently developed by Medical officially obtained the invention patent certificate awarded by National Intellectual Property Office. This process can help the gastric transfer stent system improve the corrosion resistance of the product itself, so that it can remain in the human intestinal environment for a long time, thereby better exerting medical effects and greatly improving the safety and effectiveness of the product
Kangshang Medical
- The new crown antigen self-test product has obtained the EU CE certification.The self-test product of the novel coronavirus antigen developed by Kangshang Medical was taken by a personal nasal swab. Its product performance is excellent, specific and accurate, which helps early diversion and rapid management, and further improves the ability to detect cases early
Antik Medical
- former Saint Jude electrophysiological marketing sales director Tu Quan joined Antik Medical and served as the vice president of marketing sales, helping the product commercialization process
Technology
Zhixin Semiconductor
- Release the second product family M4F series, launching Arm Cortex M4F's automotive-grade microcontroller Z20K148 is mainly aimed at various applications such as automotive body control, functional gateway, smart cockpit, new energy BMS, motor control , etc.
Wuhan Minxin Semiconductor
- Launches a full series of EML optical chip products, including 10G 1577 EML/10G 1550 TDM EML/10G DWDM EML (C band 40 waves), providing a full series of EML products and services for domestic and foreign customers. At present, this series of products has obtained customer certification and is shipped in batches
Yisixin Technology
Yisixin Technology, as a leading domestic DPU company, has launched the first domestic commercial P4 programmable cloud native intelligent network card with independent intellectual property rights, and has implemented the solution. This smart network card is the best choice for network application acceleration such as OVS, NFV, SDN vRouter, 5G UPF, etc. It has the characteristics of high performance, low latency, high flexibility, low power consumption, etc.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-